Immunovia has successfully acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer

LUND, Sweden, Oct. 7, 2024 /PRNewswire/ — Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer. Concluding the sample…